Views & Analysis Access and elimination: the future of DAAs in hepatitis C How direct-acting antivirals are transforming treatment of hepatitis C.
News Gilead ordered to pay Merck & Co $2.54 bn by US court Ruling relates to infringement of patents held by Merck subsidiary
News AbbVie taking on Gilead with eight-week hep C course Latest combination drug resulted in 97.5% cure rates across all major disease strains
Debates & Insight Sponsored The hepatitis C conundrum: balancing cost and affordability An estimated 2–3% of the world’s population is living with hepatitis C virus (HCV) – a condition that, when left untreated, can cause life-threatening damage to the liver.
Views & Analysis Many millions still untreated – but hep C boom is already ov... Gilead has led a revolution in curing hepatitis C, but now faces a slowdown.
News NHS broadens access to haemophilia A drug Hemlibra More people living with haemophilia A will be able to get access to Roche/Chugai's Hemlibra thanks to a commissioning agreement with NHS England.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
